Literature DB >> 24890070

Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis.

Debra L Foley1, Andrew Mackinnon, Vera A Morgan, Gerald F Watts, John J McGrath, David J Castle, Anna Waterreus, Cherrie A Galletly.   

Abstract

Antipsychotic drugs such as clozapine and olanzapine are associated with an increased risk for type 2 diabetes, but relatively little is known about the relationship between risk factors for type 2 diabetes established in the general population and type 2 diabetes in people with psychosis. We estimated the prevalence of established risk factors and their association with type 2 diabetes in a nationally representative sample of people with an ICD-10 psychosis (N=1642) who gave a fasting blood sample (N=1155). Logistic regression was used to summarize associations adjusted for age and sex. In this sample, whose mean duration of psychosis was 14.7 years, 12.1% (13.1% of women and 11.5% of men) had type 2 diabetes at age 18-64 years based on current fasting blood glucose levels or treatment with a hypoglycaemic drug. Risk was greatly increased in young adults compared with the general population and peaked in middle age. Risk factors in the general population were common in people with psychosis and strongly associated with type 2 diabetes in those people. Treatment with clozapine was associated with an increased risk and treatment with olanzapine with a decreased risk for type 2 diabetes. The development of diabetes or pre-diabetes may therefore influence the likelihood of treatment with olanzapine over time. The strongest predictors of type 2 diabetes in a multivariate model were a body mass index of at least 40 and treated hypercholesterolemia, followed by a body mass index between 35 and 39.9, a family history of diabetes and treated hypertension. There was minimal to no confounding of the association between type 2 diabetes and current clozapine or olanzapine treatment, but neither association remained significant after adjustment for other predictors. Longitudinal relationships among predictors are likely to be complex, and previous antipsychotic drug treatment may at least partly explain risks associated with severe obesity, dyslipidemia and hypertension. A focus on weight loss is warranted in people with psychosis, but prevention strategies for type 2 diabetes should be broadened to include those with emerging dyslipidemia, hypertension and a family history of diabetes.
Copyright © 2014 World Psychiatric Association.

Entities:  

Keywords:  Type 2 diabetes; body mass index; clozapine; hypercholesterolemia; hypertension; olanzapine; psychosis; risk factors

Year:  2014        PMID: 24890070      PMCID: PMC4102290          DOI: 10.1002/wps.20130

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  38 in total

1.  The diagnostic interview for psychoses (DIP): development, reliability and applications.

Authors:  D J Castle; A Jablensky; J J McGrath; V Carr; V Morgan; A Waterreus; G Valuri; H Stain; P McGuffin; A Farmer
Journal:  Psychol Med       Date:  2005-09-29       Impact factor: 7.723

Review 2.  Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes.

Authors:  Doreen M Rabi; Raj Padwal; Sheldon W Tobe; Richard E Gilbert; Lawrence A Leiter; Robert R Quinn; Nadia Khan
Journal:  CMAJ       Date:  2013-06-03       Impact factor: 8.262

3.  Endogenic and iatrogenic diabetes mellitus in drug-naïve schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm.

Authors:  Dan Cohen; Marc De Hert
Journal:  Neuropsychopharmacology       Date:  2011-10       Impact factor: 7.853

4.  Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.

Authors:  Jimmi Nielsen; Søren Skadhede; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-06-02       Impact factor: 7.853

5.  A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Authors:  T Scott Stroup; Joseph P McEvoy; Kimberly D Ring; Robert H Hamer; Lisa M LaVange; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Abraham M Nussbaum; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2011-07-18       Impact factor: 18.112

Review 6.  Schizophrenia and diabetes: epidemiological data.

Authors:  F Rouillon; F Sorbara
Journal:  Eur Psychiatry       Date:  2005-12       Impact factor: 5.361

7.  Patterns of antipsychotic medication use in Australia 2002-2007.

Authors:  Samantha A Hollingworth; Dan J Siskind; Lisa M Nissen; Maxine Robinson; Wayne D Hall
Journal:  Aust N Z J Psychiatry       Date:  2010-04       Impact factor: 5.744

8.  People living with psychotic illness in 2010: the second Australian national survey of psychosis.

Authors:  Vera A Morgan; Anna Waterreus; Assen Jablensky; Andrew Mackinnon; John J McGrath; Vaughan Carr; Robert Bush; David Castle; Martin Cohen; Carol Harvey; Cherrie Galletly; Helen J Stain; Amanda L Neil; Patrick McGorry; Barbara Hocking; Sonal Shah; Suzy Saw
Journal:  Aust N Z J Psychiatry       Date:  2012-06-13       Impact factor: 5.744

Review 9.  Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Elena Bonfioli; Loretta Berti; Claudia Goss; Francesca Muraro; Lorenzo Burti
Journal:  BMC Psychiatry       Date:  2012-07-12       Impact factor: 3.630

10.  Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database.

Authors:  David P J Osborn; Gus Levy; Irwin Nazareth; Irene Petersen; Amir Islam; Michael B King
Journal:  Arch Gen Psychiatry       Date:  2007-02
View more
  8 in total

1.  Comorbid Diabetes and Depression in a National Sample of Adults With Psychosis.

Authors:  Debra L Foley; Andrew Mackinnon; Vera A Morgan; David J Castle; Anna Waterreus; Cherrie A Galletly
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

2.  Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis.

Authors:  Debra L Foley; Andrew Mackinnon; Vera A Morgan; Gerald F Watts; David J Castle; Anna Waterreus; Cherrie A Galletly
Journal:  Schizophr Bull       Date:  2016-05-05       Impact factor: 9.306

Review 3.  Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus.

Authors:  Yutaka Mizuki; Shinji Sakamoto; Yuko Okahisa; Yuji Yada; Nozomu Hashimoto; Manabu Takaki; Norihito Yamada
Journal:  Int J Neuropsychopharmacol       Date:  2021-05-18       Impact factor: 5.176

4.  Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries.

Authors:  Brendon Stubbs; Ai Koyanagi; Nicola Veronese; Davy Vancampfort; Marco Solmi; Fiona Gaughran; André F Carvalho; John Lally; Alex J Mitchell; James Mugisha; Christoph U Correll
Journal:  BMC Med       Date:  2016-11-22       Impact factor: 8.775

5.  Undiagnosed Diabetes Mellitus and Associated Factors among Psychiatric Patients Receiving Antipsychotic Drugs at The University of Gondar Hospital, Northwest Ethiopia.

Authors:  Daniel Asmelash; Wondale Getnet; Belete Biadgo; Sintayehu Ambachew; Tadele Melak; Lemmesa Melese; Shiwaneh Damite; Habtamu Wondifraw Baynes; Molla Abebe
Journal:  Ethiop J Health Sci       Date:  2018-01

6.  The magnitude of undiagnosed diabetes and Hypertension among adult psychiatric patients receiving antipsychotic treatment.

Authors:  Agete Tadewos Hirigo; Tesfaye Teshome
Journal:  Diabetol Metab Syndr       Date:  2020-09-07       Impact factor: 3.320

7.  Prevalence and major risk factors of type 2 diabetes mellitus among adult psychiatric inpatients from 2005 to 2018 in Beijing, China: a longitudinal observational study.

Authors:  Fude Yang; Qiuyue Ma; Jue Liu; Botao Ma; Moning Guo; Fangchao Liu; Juan Li; Zhiren Wang; Min Liu
Journal:  BMJ Open Diabetes Res Care       Date:  2020-03

8.  Cardiovascular disease lifestyle risk factors in people with psychosis: a cross-sectional study.

Authors:  Doreen Mucheru; Mary-Claire Hanlon; Linda E Campbell; Mark McEvoy; Lesley MacDonald-Wicks
Journal:  BMC Public Health       Date:  2018-06-15       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.